Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-κB activation

Cancer Research

Volumn 64, Issue 18, 2004, Pages 6482-6488

  Seo, Kook Heon ^a   Lee, Hyun Suk ^a   Jung, Bongnam ^a   Ko, Hyun Mi ^a   Choi, Jung Hwa ^a   Park, Sung Jun ^a   Choi, Il Hwan ^b   Lee, Hern Ku ^b   Im, Suhn Young ^a  

^a Chonnam National University   (South Korea)

^b Chonbuk National University Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANGIOGENIC FACTOR; ANTIESTROGEN; ESTROGEN; GENE PRODUCT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIGEL; MESSENGER RNA; PARTHENOLIDE; PHOSPHOLIPASE A2; SYNAPTOTAGMIN; TAMOXIFEN; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENDOMETRIUM CARCINOMA; ENZYME ACTIVATION; ESTROGEN ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ENDOMETRIAL NEOPLASMS; ESTRADIOL CONGENERS; FEMALE; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN-1; INTERLEUKIN-8; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PHOSPHOLIPASES A; PLATELET ACTIVATING FACTOR; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 4644357258     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2774     Document Type: Article

References (50)

1. Johns A, Freay AD, Fraser W, et al. Disruption of estrogen receptor gene prevents 17 beta estradiol-induced angiogenesis in transgenic mice. Endocrinology 1996;137:4511-3.
2. Losordo DW, Isner JM. Estrogen and angiogenesis: a review. Arterioscler Thromb Vasc Biol 2001;21:6-12.
3. Hyder SM, Stancel GM. Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. Mol Endocrinol 1999;13:806-11.
4. Yasuda Y, Masuda S, Chikuma M, et al. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 1998;273:25381-7.
5. McLaren J, Prentice A, Charnock-Jones DS, et al. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Investig 1996;98:482-9.
6. Bulun SE, Zeitoun KM, Takayama K, et al. Estrogen biosynthesis in endometriosis: molecular basis and clinical relevance. J Mol Endocrinol 2000;25:35-42.
7. Fujimoto J, Hirose R, Sakaguchi H, et al. Estrogen dependency in uterine endometrial cancers. Oncology 1998;55(Suppl);1:53-9.
8. Morales DE, McGowan KA, Grant DS, et al. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 1995;91:755-63.
9. Gay JC. Mechanism and regulation of neutrophil priming by platelet-activating factor. J Cell Physiol 1993;156:189-97.
10. Fukuda Al, Breuel KF. Effect of platelet-activating factor on embryonic development and implantation in the mouse. Hum Reprod 1996;11:2746-9.
11. Shukla SD. Platelet-activating factor receptor and signal transduction mechanisms. FASEB J 1992;6:2296-301.
12. Buttke TM, Sandstrom PA. Redox regulation of programmed cell death in lymphocytes. Free Radic Res 1995;22:389-97.
13. Braquet P, Touqui L, Shen TY, et al. Perspectives in platelet-activating factor research. Pharmacol Rev 1987;39:97-145.
14. Baeuerle PA, Baltimore D. Activation of DNA-binding activity in an apparently cytoplasmic precursors of the NF-kappaB transcription factor. Cell 1988;53:211-7.
15. Baeuerle PA, Henkel T. Function and activation of NF-kappaB in the immune system. Annu Rev Immunol 1994;12:141-79.
16. Han SJ, Choi JH, Ko HM, et al. Glucocorticoids prevent NF-kappaB activation by inhibiting the early release of platelet-activating factor in response to lipopolysaccharide. Eur J Immunol 1999;29:1334-41.
17. Choi JH, Ko HM, Kim JW, et al. Platelet-activating factor-induced early activation of NF-kappaB plays a crucial role for organ clearance of Candida albicans. J Immunol 2001;166:5139-44.
18. Ko HM, Seo KH, Han SJ, et al. NF-κB dependency of platelet-activating factor-induced angiogenesis. Cancer Res 2002;62:1809-14.
19. Li L, Yasuda K, Matsubara T, et al. Estrogen effects on platelet-activating factor and platelet-activating factor acetylhydrolase activity in rat uterus during the late stages of pregnancy. Prostaglandins Other Lipid Mediat 1999;57:219-30.
20. Nakayama R, Yasuda K, Okumura T, et al. Effect of 17 beta-estradiol on PAF and prostaglandin levels in oophorectomized rat uterus. Biochem Biophys Acta 1999;1085:235-40.
21. Shimizu T, Mutoh H, Kato S. Platelet-activating factor receptor. Gene structure and tissue-specific regulation. Adc Exp Med Biol 1996;416:79-84.
22. Yoshimura T, Ohshige A, Maeda T, et al. Estrogen replacement therapy decreases platelet-activating factor-acetylhydrolase activity in post-menopausal women. Maturitas 1999;31(3):249-53.
23. Ahmed A, Shoaibi MA, Plevin R, et al. Oestradiol-17 beta modulates PAF-evoked phospholipase D activity but not inositide-lipid hydrolysis in human endometrial cell line, HEC-1B. Cell Signaling 1995;7:403-9.
24. Kim I, Moon SO, Koh KN, et al. Molecular cloning, expression, and characterization of angiopoietin-related protein. Angiopoietin-related protein induces endothelial cell sprouting. J Biol Chem 1999;274:26523-8.
25. Choi IH, Shin YM, Park JS, et al. Immunoglobulin E-dependent active fatal anaphylaxis in mast cell-deficient mice. J Exp Med 1998;188:1587-92.
26. 2 superfamily of signal transduction enzymes. Trends Biochem Sci 1997;22:1-2.
27. 2. Crit Rev Immunol 1997;17:225-83.
28. 2+-dependent translocation domain with homology to PKC and GAP. Cell 1991;65:1043-51.
29. 2 is phosphorylated and activated by MAP kinase. Cell 1993;72:269-78.
30. 2. J Biol Chem 1996;271:27723-9.
31. Santen RJ, Song RX, McPherson R, et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 2002;80:239-56.
32. 2 activity in human endometrial stromal cells. Prostaglandins 1996;51:191-201.
33. 2 activity in human endometrium during the menstrual cycle. J Endocrinol 1985;107:183-9.
34. 2 activity in the rat uterus: modulation by steroid hormones. Prostaglandins 1982;23:619-30.
35. Stoltz RA, Abraham NG, Laniado-Schwartzman M. The role of NF-kappaB in the angiogenic response of coronary microvessel endothelial cells. Proc Natl Acad Sci USA 1996;93:2832-7.
36. Shono T, Ono M, Izumi H, et al. Involvement of the transcription factor NF-kappaB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol Cell Biol 1996;16:4231-9.
37. Xu L, Xie K, Mukaida N, et al. Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells. Cancer Res 1999;59:5822-9.
38. Yoshida S, Ono M, Shono T, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997;17:4015-23.
39. Bhat-Nakshatri P, Newton TR, Goulet R Jr, et al. NF-kappaB activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin 1 alpha. Proc Natl Acad Sci 1998;95:6971-6.
40. Kitajima I, Unoki K, Maruyama I. Phosphorothioate oligodeoxy-nucleotides inhibit basic fibroblast growth factor-induced angiogenesis in vitro and in vivo. Antisense. Nucleic Acid Drug Dev 1999;9:233-9.
41. Chilov D, Kukk E, Taira S, et al. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem 1997;272:25176-83.
42. Abeyama K, Eng W, Jester JV, et al. A role for NF-kappaB-dependent gene transcription in sunburn. J Clin Investig 2000;105:1751-9.
43. Stein B, Yang MX. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappaB and C/EBP beta. Mol Cell Biol 1995;15:4971-9.
44. Speir E, Yu ZX, Takeda K, et al. Competition for p300 regulates transcription by estrogen receptors and nuclear factor-kappaB in human coronary smooth muscle cells. Circ Res 2000;87:1006-11.
45. Evans MJ, Eckert A, Lai K, et al. Reciprocal antagonism between estrogen receptor and NF-kappaB activity in vivo. Cir Res 2001;89:823-30.
46. Kanda N, Watanabe S. 17beta-Estradiol inhibits the production of RANTES in human keratinocytes. J Investig Dermatol 2003;120:420-7.
47. Shyamala G, Guiot MC. Activation of kappaB-specific proteins by estradiol. Proc Natl Acad Sci USA 1992;89:10628-32.
48. Cerillo G, Rees A, Manchanda N, et al. The estrogen receptor regulates NF-kappaB and AP-1 activity in a cell-specific manner. J Steroid Biochem Mol Biol 1998;67:79-88.
49. Touqui L, Jacquemin C, Dumarey C, et al. 1-O-Alkyl-2-acyl-sn-glycero-3- phosphorylcholine is the precursor of platelet-activating factor in stimulated rabbit platelets. Evidence for an alkylacetyl-glycerophosphorylcholine cycle. Biochim Biophys Acta 1985;833:111-8.
50. Gomez-Cambronero J, Nieto ML, Mato JM, et al. Modulation of lyso-platelet-activating factor: acetyl-CoA acetyltransferase from rat splenic microsomes. The role of calcium ions. Biochim Biophys Acta 1985;845:511-5.